BACKGROUND: Although many treatments for advanced gastric cancer have been developed, systemic therapy remains elusive. METHODS: The author reviewed data on recent phase II and III trials of the main new agents and combinations. RESULTS: Chemotherapy appears to improve survival of patients with advanced disease, albeit slightly. New drugs that might improve response rates and survival include the taxanes. CONCLUSIONS: New combinations, including the taxanes, must be designed and evaluated to further improve the outcome for patients with advanced gastric cancer.
BACKGROUND: Although many treatments for advanced gastric cancer have been developed, systemic therapy remains elusive. METHODS: The author reviewed data on recent phase II and III trials of the main new agents and combinations. RESULTS: Chemotherapy appears to improve survival of patients with advanced disease, albeit slightly. New drugs that might improve response rates and survival include the taxanes. CONCLUSIONS: New combinations, including the taxanes, must be designed and evaluated to further improve the outcome for patients with advanced gastric cancer.
Authors: C Kollmannsberger; D Quietzsch; C Haag; T Lingenfelser; M Schroeder; J T Hartmann; W Baronius; V Hempel; M Clemens; L Kanz; C Bokemeyer Journal: Br J Cancer Date: 2000-08 Impact factor: 7.640